A detailed history of Janus Henderson Group PLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 23,254 shares of SUPN stock, worth $739,942. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,254
Previous 23,525 1.15%
Holding current value
$739,942
Previous $802,000 22.44%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$25.99 - $33.85 $7,043 - $9,173
-271 Reduced 1.15%
23,254 $622,000
Q1 2024

May 15, 2024

BUY
$27.11 - $35.17 $54 - $70
2 Added 0.01%
23,525 $802,000
Q4 2023

Feb 14, 2024

SELL
$22.72 - $29.68 $976 - $1,276
-43 Reduced 0.18%
23,523 $680,000
Q3 2023

Nov 14, 2023

BUY
$27.57 - $32.91 $82 - $98
3 Added 0.01%
23,566 $649,000
Q2 2023

Aug 14, 2023

SELL
$29.91 - $38.73 $777 - $1,006
-26 Reduced 0.11%
23,563 $708,000
Q1 2023

May 15, 2023

BUY
$34.93 - $42.03 $450,387 - $541,934
12,894 Added 120.56%
23,589 $854,000
Q3 2022

Nov 14, 2022

BUY
$28.79 - $35.41 $345 - $424
12 Added 0.11%
10,695 $362,000
Q2 2022

Aug 15, 2022

SELL
$25.33 - $34.25 $1.36 Million - $1.83 Million
-53,543 Reduced 83.37%
10,683 $309,000
Q1 2022

May 16, 2022

SELL
$28.51 - $32.9 $495,931 - $572,295
-17,395 Reduced 21.31%
64,226 $2.08 Million
Q4 2021

Feb 14, 2022

BUY
$26.37 - $34.22 $197,616 - $256,444
7,494 Added 10.11%
81,621 $2.38 Million
Q3 2021

Nov 16, 2021

SELL
$23.54 - $31.39 $305,619 - $407,536
-12,983 Reduced 14.9%
74,127 $1.98 Million
Q2 2021

Aug 16, 2021

SELL
$26.72 - $33.19 $316,712 - $393,401
-11,853 Reduced 11.98%
87,110 $2.68 Million
Q1 2021

May 17, 2021

BUY
$24.15 - $31.45 $594,573 - $774,299
24,620 Added 33.12%
98,963 $2.59 Million
Q4 2020

Feb 16, 2021

BUY
$17.7 - $25.81 $127,723 - $186,244
7,216 Added 10.75%
74,343 $1.87 Million
Q3 2020

Nov 16, 2020

BUY
$20.2 - $25.05 $111,342 - $138,075
5,512 Added 8.95%
67,127 $1.4 Million
Q2 2020

Aug 14, 2020

BUY
$17.09 - $24.89 $503,693 - $733,582
29,473 Added 91.7%
61,615 $1.46 Million
Q1 2020

May 14, 2020

BUY
$14.45 - $24.69 $24,492 - $41,849
1,695 Added 5.57%
32,142 $578,000
Q4 2019

Feb 18, 2020

SELL
$19.93 - $29.13 $12.7 Million - $18.5 Million
-635,180 Reduced 95.43%
30,447 $722,000
Q3 2019

Nov 14, 2019

BUY
$25.47 - $33.37 $130,075 - $170,420
5,107 Added 0.77%
665,627 $18.3 Million
Q2 2019

Jul 31, 2019

SELL
$29.96 - $38.87 $307,839 - $399,389
-10,275 Reduced 1.53%
660,520 $21.9 Million
Q1 2019

Apr 30, 2019

BUY
$32.77 - $41.99 $981,428 - $1.26 Million
29,949 Added 4.67%
670,795 $23.5 Million
Q4 2018

Feb 06, 2019

SELL
$30.84 - $49.51 $570,046 - $915,142
-18,484 Reduced 2.8%
640,846 $21.3 Million
Q3 2018

Nov 09, 2018

SELL
$42.7 - $56.55 $258,847 - $342,806
-6,062 Reduced 0.91%
659,330 $33.2 Million
Q2 2018

Aug 10, 2018

BUY
$44.1 - $59.85 $5.22 Million - $7.08 Million
118,289 Added 21.62%
665,392 $39.8 Million
Q1 2018

May 14, 2018

BUY
$37.15 - $46.9 $4.57 Million - $5.77 Million
123,082 Added 29.03%
547,103 $25.1 Million
Q4 2017

Feb 09, 2018

BUY
$36.4 - $42.6 $5.75 Million - $6.73 Million
157,875 Added 59.32%
424,021 $16.9 Million
Q3 2017

Nov 14, 2017

BUY
$36.75 - $49.65 $9.78 Million - $13.2 Million
266,146
266,146 $0

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.7B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.